Insider Selling: CAMP4 Therapeutics (NASDAQ:CAMP) Director Sells $144,081.00 in Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Director Andrew Schwab sold 32,018 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $4.50, for a total transaction of $144,081.00. Following the completion of the transaction, the director owned 2,433,280 shares of the company’s stock, valued at approximately $10,949,760. This represents a 1.30% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

CAMP4 Therapeutics Stock Performance

Shares of CAMP4 Therapeutics stock opened at $4.48 on Monday. The firm’s 50-day simple moving average is $4.12 and its 200-day simple moving average is $4.34. CAMP4 Therapeutics Corporation has a twelve month low of $1.41 and a twelve month high of $7.75. The firm has a market cap of $281.12 million, a P/E ratio of -1.93 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. The business had revenue of $1.78 million during the quarter. On average, equities analysts forecast that CAMP4 Therapeutics Corporation will post -0.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on CAMP shares. Zacks Research upgraded CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th. Chardan Capital set a $6.50 price target on CAMP4 Therapeutics and gave the company a “buy” rating in a research note on Wednesday, June 10th. Piper Sandler reiterated an “overweight” rating and issued a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. Weiss Ratings upgraded CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. Finally, UBS Group set a $15.00 price objective on CAMP4 Therapeutics in a report on Friday, August 14th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.56.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of CAMP. China Universal Asset Management Co. Ltd. acquired a new stake in CAMP4 Therapeutics during the 4th quarter valued at $61,000. Jefferies Financial Group Inc. bought a new position in CAMP4 Therapeutics in the 4th quarter valued at $70,000. State Street Corp boosted its stake in CAMP4 Therapeutics by 52.7% in the fourth quarter. State Street Corp now owns 39,700 shares of the Wireless communications provider’s stock worth $243,000 after purchasing an additional 13,700 shares in the last quarter. Bank of America Corp DE acquired a new position in CAMP4 Therapeutics in the fourth quarter worth $86,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of CAMP4 Therapeutics during the fourth quarter worth $115,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.